Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (symbol: VXRT) is a clinical-stage biotechnology company dedicated to transforming vaccine delivery through its innovative oral recombinant vaccine platform. Founded in 2004, Vaxart's primary focus is the development of vaccines in tablet form, offering a needle-free alternative that is easy to administer and store. This proprietary technology aims to revolutionize the global vaccine market, addressing common diseases such as Coronavirus, Norovirus, Seasonal Influenza, Respiratory Syncytial Virus (RSV), and Human Papillomavirus (HPV).
Headquartered in the United States, Vaxart operates in a single segment focused exclusively on the discovery and development of these groundbreaking oral recombinant protein vaccines. The company has made significant strides in the clinical development of its diverse pipeline, with several candidates currently undergoing trials. Vaxart’s oral vaccines are designed to simplify distribution and administration, potentially increasing vaccination rates and improving global health outcomes.
Recent achievements for Vaxart include the ongoing development and testing of its oral COVID-19 vaccine candidate, which has shown promise in preclinical studies and early-phase clinical trials. This innovation could play a crucial role in global vaccination efforts, especially in regions where cold-chain requirements pose logistical challenges. Other notable projects include the development of oral vaccines for Norovirus and Influenza, which are also advancing through various stages of clinical testing.
Financially, Vaxart remains focused on strategic partnerships and funding opportunities to support its research and development initiatives. The company's recent financial results for the full year ended December 31, 2023, and the first quarter ended March 31, 2024, reflect its ongoing commitment to advancing its oral vaccine candidates through clinical trials and towards regulatory approval.
For more information and the latest updates, contact Vaxart Media Relations: Mark Herr (mherr@vaxart.com, 203-517-8957) or Investor Relations: Andrew Blazier (IR@vaxart.com, 646-871-8486).
Vaxart, a clinical-stage biotechnology company, announced new pre-clinical data showing its oral COVID-19 vaccine significantly reduced lung inflammation in hamster models. Published in Nature Medicine, the study highlighted a substantial reduction in viral load and robust antibody responses. CEO Andrei Floroiu emphasized the vaccine's room-temperature stability, enhancing transport and storage. Phase I trial data is anticipated next week. The selected vaccine candidate also targets the nucleocapsid protein, potentially improving cross-protection.
Vaxart, Inc. (NASDAQ: VXRT) will host an investor panel on November 19, 2020, featuring key opinion leaders discussing their oral vaccine technology aimed at combating COVID-19 and Norovirus. The panel includes insights on immunity, disease prevention, and Vaxart's investigational vaccines. Management will update on their Phase 1 trial for Norovirus and provide preclinical data for their oral COVID-19 vaccine candidate, VXA-CoV2-1. The company emphasizes the potential advantages of oral vaccines over traditional injections, including ease of distribution and administration.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 – Vaxart, Inc. (NASDAQ: VXRT) announced participation in two upcoming virtual investor conferences. The Jefferies 2020 Virtual London Healthcare Conference will take place from November 17-19, with Vaxart's presentation scheduled for November 19 at 2:20 p.m. ET. Additionally, the Piper Sandler 32nd Annual Virtual Healthcare Conference is set for December 1-3. Vaxart focuses on developing oral vaccines for various infectious diseases, including COVID-19. For further details, visit their investors section.
Vaxart announced the completion of enrollment in its Phase 1 trial for VXA-CoV2-1, an oral COVID-19 vaccine candidate. The trial data show significant viral load reduction and strong antibody responses in a hamster model. The company reported a net loss of $8.1 million for Q3 2020, an increase from $5.3 million in Q3 2019, primarily due to higher operating expenses. Revenue dropped to $265,000, down from $454,000 in Q3 2019, attributed mainly to reduced contract activities with Janssen. Vaxart ended Q3 with $133.4 million in cash, boosted by a recent stock issuance.
Vaxart, Inc. (NASDAQ: VXRT) reported promising results from its Hamster Challenge Study for its oral COVID-19 vaccine candidate. The study indicated a significant reduction in lung viral load by 4-5 logs in vaccinated hamsters versus unvaccinated ones. Additionally, antibody response was strong, with serum IgG levels exceeding 10,000. The oral vaccine performed comparably to intranasal options in preventing weight loss and lung complications. CEO Andrei Floroiu emphasized the convenience of their room-temperature-stable oral vaccine, which could be a practical alternative to injectable vaccines.
Vaxart (NASDAQ: VXRT) released promising results from its Hamster Challenge Study, indicating that all hamsters receiving two oral doses of its COVID-19 vaccine candidate did not experience systemic weight loss, a key protective measure. Dr. Sean Tucker highlighted that these results validate the vaccine's potential against COVID-19 as the company prepares for human clinical trials. The study showed that unvaccinated hamsters lost significant weight and exhibited lung issues, whereas vaccinated ones maintained or gained weight (p<0.001). Vaxart aims to provide a convenient oral vaccine solution.
Vaxart, a clinical-stage biotechnology firm, announced the dosing of the first subject in its Phase 1 study for VXA-CoV2-1, an oral COVID-19 vaccine candidate. The open-label trial aims to assess safety and immunogenicity in 48 healthy adults. Preclinical data suggest the vaccine can trigger significant systemic and mucosal immune responses. Enrollment is expected to finish by early November 2020, with initial clinical data available shortly thereafter. Vaxart's oral tablet vaccine may simplify distribution and administration compared to traditional injectable vaccines.
Vaxart, a clinical-stage biotechnology company, announced the FDA's approval for its Investigational New Drug (IND) application for a Phase 1 trial of its oral COVID-19 vaccine. Recruitment for the trial is set to start this month, targeting healthy adults aged 18 to 55. The primary focus is on safety and reactogenicity, while secondary aims include measuring immune response duration. Additionally, Vaxart expects results from hamster and non-human primate challenge studies this October. The oral vaccine platform offers advantages like easier distribution due to stability at room temperature.
Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of Karen J. Wilson to its Board of Directors and as chair of the Audit Committee. With over 30 years in finance within the life sciences sector, Wilson's experience is expected to bolster Vaxart's growth as they advance their oral COVID-19 vaccine candidate. CEO Andrei Floroiu highlighted her expertise as a significant asset for the company, which is focused on developing oral vaccines for various infectious diseases. Vaxart’s innovative tablet vaccines aim to simplify distribution and enhance pandemic response.
Vaxart, Inc. (NASDAQ: VXRT) recently announced a study in the Journal of Infectious Diseases highlighting that norovirus gastroenteritis costs the U.S. approximately $10.6 billion annually, primarily due to sporadic cases rather than publicized outbreaks. Conducted by PHICOR, the study suggests over 50% of these costs occur during winter months, emphasizing the need for timely preventative measures. Furthermore, productivity losses account for 89% of overall costs, underscoring the substantial economic burden. Vaxart supports the research to advance its oral norovirus vaccine program.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
What is Vaxart, Inc. known for?
When was Vaxart, Inc. founded?
What is Vaxart's proprietary technology?
Where is Vaxart, Inc. headquartered?
What are some diseases Vaxart's vaccines target?
How is Vaxart's oral vaccine beneficial?
What recent achievements has Vaxart made?
What is Vaxart's financial condition?
How can I contact Vaxart for more information?
What segment does Vaxart operate in?
